Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
暂无分享,去创建一个
O. Hes | L. Holubec | T. Kubíková | V. Přibáň | K. Pivovarcikova | J. Polívka | I. Třešková | V. Priban
[1] Yi-long Wu,et al. EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now? , 2016, Trends in pharmacological sciences.
[2] K. Chester,et al. Ipilimumab and Bevacizumab in Glioblastoma. , 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).
[3] H. Kluger,et al. Evolving Immunotherapy Approaches for Renal Cell Carcinoma , 2016, Current Oncology Reports.
[4] P. Lowenstein,et al. Recent advances and future of immunotherapy for glioblastoma , 2016, Expert opinion on biological therapy.
[5] A. Brandes,et al. Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences , 2016, Current Treatment Options in Oncology.
[6] K. Margolin. The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma , 2016, Current Treatment Options in Oncology.
[7] M. Yalon,et al. Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors , 2016, Journal of Neuro-Oncology.
[8] O. Topolcan,et al. Current status of biomarker research in neurology , 2016, EPMA Journal.
[9] A. Vortmeyer,et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. , 2016, The Lancet. Oncology.
[10] R. Rosell,et al. Trends in immunotherapy for brain metastases. , 2016, The Lancet. Oncology.
[11] M. Aglietta,et al. Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer? , 2016, International journal of molecular sciences.
[12] H. Colman,et al. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future , 2016, Current Treatment Options in Oncology.
[13] T. Fuereder. Immunotherapy for head and neck squamous cell carcinoma , 2016, memo - Magazine of European Medical Oncology.
[14] H. Colman,et al. Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM). , 2016 .
[15] R. Stupp,et al. EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma. , 2016 .
[16] T. Cloughesy,et al. Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143. , 2016 .
[17] N. Tran,et al. Safety and antitumor activity of hypofractionated stereotactic irradiation (HFSRT) with pembrolizumab (Pembro) and bevacizumab (Bev) in patients (pts) with recurrent high grade gliomas: Preliminary results from phase I study. , 2016 .
[18] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[19] Hongyang Zhao,et al. Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials. , 2016, Molecular and clinical oncology.
[20] A. Zaniboni,et al. The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside , 2016, Cancer Chemotherapy and Pharmacology.
[21] R. Montironi,et al. Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? , 2016, Oncology reviews.
[22] F. Worden,et al. Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors , 2016, OncoTargets and therapy.
[23] J. Ahn,et al. Pembrolizumab for the treatment of non-small cell lung cancer , 2016, Expert opinion on biological therapy.
[24] G. Fuller,et al. PD-L1 expression and prognostic impact in glioblastoma. , 2016, Neuro-oncology.
[25] Ș. Purcaru,et al. New perspectives in glioblastoma antiangiogenic therapy , 2015, Contemporary oncology.
[26] F. Janku,et al. Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet? , 2015, Expert review of molecular diagnostics.
[27] Kristen L. Jones,et al. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model , 2015, Cancer Immunology Research.
[28] Ye Chen,et al. Tumor microenvironment: Sanctuary of the devil. , 2015, Cancer letters.
[29] D. Hafler,et al. Prospects of immune checkpoint modulators in the treatment of glioblastoma , 2015, Nature Reviews Neurology.
[30] J. Sarkaria,et al. A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. , 2015, Neuro-oncology.
[31] M. Weller,et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. , 2015, Neuro-oncology.
[32] M. Ge,et al. Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies , 2015, Oncotarget.
[33] K. Aldape,et al. Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). , 2015, Neuro-oncology.
[34] R. Bourgon,et al. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Jing Liu,et al. Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme , 2015, BioMed research international.
[36] J. Engh,et al. Outcomes of the ACT III Study: Rindopepimut (CDX-110) Therapy for Glioblastoma. , 2015, Neurosurgery.
[37] L. Recht,et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. , 2015, Neuro-oncology.
[38] Katrina H. Smith,et al. A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients , 2015, Clinical Cancer Research.
[39] K. Peters,et al. Use of bevacizumab in recurrent glioblastoma. , 2015, CNS oncology.
[40] P. Ascierto,et al. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[41] J. Raizer,et al. Bevacizumab in high-grade gliomas: past, present, and future , 2015, Expert review of anticancer therapy.
[42] A. Sloan,et al. Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme. , 2015, CNS oncology.
[43] M. Gilbert,et al. Current challenges in designing GBM trials for immunotherapy , 2015, Journal of Neuro-Oncology.
[44] J. Gavard,et al. PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma , 2014, Oncotarget.
[45] Robert J Dempsey,et al. Science Times , 2022 .
[46] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[47] A. Heimberger,et al. Immunotherapy for Primary Brain Tumors: No Longer a Matter of Privilege , 2014, Clinical Cancer Research.
[48] K. Ashkan,et al. DCVax®-L—Developed by Northwest Biotherapeutics , 2014, Human vaccines & immunotherapeutics.
[49] G. K. Gray,et al. NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age , 2014, Expert review of neurotherapeutics.
[50] Helen Wheeler,et al. Antiangiogenic therapy for high-grade glioma. , 2014, The Cochrane database of systematic reviews.
[51] K. Aldape,et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.
[52] R. Vernhout,et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. , 2014, The Lancet. Oncology.
[53] Jiri Polivka,et al. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. , 2014, Pharmacology & therapeutics.
[54] O. Topolcan,et al. New treatment paradigm for patients with anaplastic oligodendroglial tumors. , 2014, Anticancer research.
[55] Y. Cheng,et al. Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors , 2014, Clinical Cancer Research.
[56] K. Aldape,et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[57] K. Hoang-Xuan,et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[58] Susan M. Chang,et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. , 2014, Neuro-oncology.
[59] O. Topolcan,et al. Isocitrate Dehydrogenase-1 Mutations as Prognostic Biomarker in Glioblastoma Multiforme Patients in West Bohemia , 2014, BioMed research international.
[60] B. Becher,et al. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection , 2013, The Journal of experimental medicine.
[61] T. Mikkelsen,et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] A. Dicker,et al. Epidermal Growth Factor Receptor Mutation Status and Rad51 Determine the Response of Glioblastoma to Multimodality Therapy with Cetuximab, Temozolomide, and Radiation , 2013, Front. Oncol..
[63] G. Fountzilas,et al. A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas , 2013, Journal of Neurology.
[64] J. Barnholtz-Sloan,et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.
[65] S. Phuphanich,et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma , 2012, Cancer Immunology, Immunotherapy.
[66] O. Topolcan,et al. New molecularly targeted therapies for glioblastoma multiforme. , 2012, Anticancer research.
[67] W. Mason,et al. Phase II study of PX-866 in recurrent glioblastoma. , 2012, Neuro-oncology.
[68] J. Wolchok,et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. , 2012, The Lancet. Oncology.
[69] L. Liau,et al. Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients , 2012, PloS one.
[70] J. Hainsworth,et al. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. , 2012, Clinical advances in hematology & oncology : H&O.
[71] Aaron S. Gajadhar,et al. In Situ Analysis of Mutant EGFRs Prevalent in Glioblastoma Multiforme Reveals Aberrant Dimerization, Activation, and Differential Response to Anti-EGFR Targeted Therapy , 2012, Molecular Cancer Research.
[72] G. Riggins,et al. Molecular targeting of glioblastoma: Drug discovery and therapies. , 2011, Trends in molecular medicine.
[73] A. Friedman,et al. The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma , 2011, Clinical Cancer Research.
[74] R. McLendon,et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. , 2011, Neuro-oncology.
[75] Paul S Mischel,et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[76] P. Gutin,et al. Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches , 2011, Radiation oncology.
[77] S. Nelson,et al. Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy , 2010, Clinical Cancer Research.
[78] G. Maira,et al. Assessment of angiogenesis by CD105 and nestin expression in peritumor tissue of glioblastoma. , 2010, International journal of oncology.
[79] P. Wen,et al. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. , 2010, International journal of radiation oncology, biology, physics.
[80] J. Reijneveld,et al. UvA-DARE ( Digital Academic Repository ) Angiogenesis inhibition in high grade glioma Verhoeff , 2009 .
[81] J. Hainsworth,et al. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first‐line treatment of patients with glioblastoma multiforme , 2010, Cancer.
[82] Thomas Benner,et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[83] T. Cloughesy,et al. mTOR signaling in glioblastoma: lessons learned from bench to bedside , 2010, Neuro-oncology.
[84] W. Mason,et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[85] Jan Goffin,et al. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study , 2010, Journal of Neuro-Oncology.
[86] H. Fine,et al. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. , 2010, Neuro-oncology.
[87] T. Mikkelsen,et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] A. Kaye,et al. The EGFRvIII variant in glioblastoma multiforme , 2009, Journal of Clinical Neuroscience.
[89] P. Mischel,et al. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM) , 2009, Journal of Neuro-Oncology.
[90] M. Kosteljanetz,et al. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours , 2009, Acta oncologica.
[91] P. Wen,et al. Novel anti-angiogenic therapies for malignant gliomas , 2008, The Lancet Neurology.
[92] T. Mikkelsen,et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] R. Sciot,et al. Postoperative Adjuvant Dendritic Cell–Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme , 2008, Clinical Cancer Research.
[94] J. Hatazawa,et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. , 2008, Journal of neurosurgery.
[95] John Sampson,et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[96] D. Reardon,et al. Molecularly targeted therapy for malignant glioma , 2007, Cancer.
[97] Li Zhang,et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[98] D. Bigner,et al. Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function , 2007, Clinical Cancer Research.
[99] R. Perona,et al. Long term responses with cetuximab therapy in glioblastoma multiforme , 2006, Cancer biology & therapy.
[100] D. Silbergeld,et al. Phase II Study of Concurrent Continuous Temozolomide (TMZ) and Tamoxifen (TMX) for Recurrent Malignant Astrocytic Gliomas , 2004, Journal of Neuro-Oncology.
[101] D. Nam,et al. Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance. , 2004, Oncology reports.
[102] G. Broggi,et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma , 2003, Journal of Neuro-Oncology.
[103] A. Brandes,et al. Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[104] P. Gaudreau,et al. Immunotherapy Comes of Age in Lung Cancer , 2017, Clinical lung cancer.
[105] A. Lenis,et al. Immunotherapy for the Treatment of Urothelial Carcinoma , 2017, The Journal of urology.
[106] O. Topolcan,et al. Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma. , 2016, Anticancer research.
[107] D. Taheri,et al. Evaluation of Endoglin as an Angiogenesis Marker in Glioblastoma. , 2015, Iranian journal of pathology.
[108] Katrina H. Smith,et al. Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas , 2014, Journal of Neuro-Oncology.
[109] M. Roizen,et al. Hallmarks of Cancer: The Next Generation , 2012 .
[110] H. Poulsen,et al. Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme , 2012, Journal of Neuro-Oncology.
[111] C. Kruchko,et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. , 2012, Neuro-oncology.
[112] Suzanne Kamel-Reid,et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation , 2009, Cancer Chemotherapy and Pharmacology.
[113] J. Uhm. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2009 .
[114] G. Riggins,et al. A survey of glioblastoma genomic amplifications and deletions , 2009, Journal of Neuro-Oncology.
[115] R. McLendon,et al. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma , 2009, Journal of Neuro-Oncology.
[116] A. Ostman. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. , 2004, Cytokine & growth factor reviews.
[117] O. Topolcan,et al. Glioblastoma Multiforme – a Review of Pathogenesis , Biomarkers and Therapeutic Perspectives , 2022 .